Browse Studies — Arctuva

Phase 1

An Open-Label, Multicenter, Phase 1/2 Dose-Escalation and Expansion Trial Evaluating the Safety and Efficacy of FT839 in Participants With Autoimmune Diseases

The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose …

ANCA-Associated Vasculitis (AAV)Idiopathic Inflammatory Myositis (IIM)Rheumatoid Arthritis (RA)+2 more

Estimated

~$10 – $8,750

Fate TherapeuticsNCT07800871

Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary…

Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)Idiopathic Inflammatory Myositis (IIM)Systemic Sclerosis (SSc)+2 more

Estimated

~$10 – $8,750

Fate TherapeuticsNCT06308978

Phase 2

A Phase 2-Phase 3, Double-blinded, Randomized, Dose-repeating, Cross-over Study to Assess the Safety and Efficacy of Allogeneic ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM)

The goal of this clinical trial is to learn about how an umbilical cord lining-derived stem cell (ULSC) product performs when treating Dermatomyositis/Polymyos…

Idiopathic Inflammatory Myositis (IIM)DERMATOMYOSITIS OR POLYMYOSITIS

Estimated

~$10 – $8,750

Restem, LLC.NCT07160205